Clinical trials: Nonalcoholic Fatty Liver
Non-Alcoholic Fatty Liver Disease, Type2 Diabetes
Characteristics of NAFLD Among Type 2 Diabetes Patients
Type 2 diabetes patients have a high risk of developing NAFLD. This was confirmed during previous research, a high prevalence of NAFLD among type 2 diabetes mellitus patients was found.
- Trial name
- NCT04999124
- Testing
- Screening and studying characteristics
- Where
- Belgium
- Volunteers
- 1,762 people
- Sponsor
- Ziekenhuis Oost-Limburg
Nonalcoholic Steatohepatitis
Dose Escalation Study of Kylo-0603 in Healthy Subjects
This clinical trial is the first-in-human study of Kylo-0603. The purpose of this randomized, double-blind, placebo-controlled phase 1 study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and effect of…
- Trial name
- NCT06365580
- Testing
- Kylo-0603 capsule
- Where
- China
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Kylonova (Xiamen) Biopharma co., LTD.
Non-alcoholic Fatty Liver Disease
Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver Progression
Non-alcoholic fatty liver disease (NAFLD) is a common disorder, affecting ~30% of people in the general population and up to 96% of obese individuals.
- Trial name
- NCT02267148
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- UNC Nutrition Research Institute
Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
This study involves research about an investigational medicine called metreleptin. The reason for this study is to find out how metreleptin can improve non-alcoholic steatohepatitis or nonalcoholic fatty liver disease associated…
- Conditions
- Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis, Lipodystrophy
- Trial name
- NCT01679197
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan
Non-Alcoholic Fatty Liver Disease, Insulin Resistance
Effects of Carnitine Supplementation on Liver and Muscle
It will be evaluated whether carnitine, a dietary supplement, reduces liver fat and improves metabolism in individuals who have a high concentration of fat within their liver.
- Trial name
- ECLIPSE (NCT03439917)
- Testing
- L-Carnitine tartrate, Meal Replacement Drink, Maltodextrin
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Nottingham
NASH - Nonalcoholic Steatohepatitis
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 from those without.
- Trial name
- NCT04054310
- Testing
- Liver Multi Scan
- Where
- 7 sites in United States
- Volunteers
- 225 people
- Sponsor
- Perspectum
Hepatitis C, Hepatitis B
Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound
Liver fibrosis is an important public health problem, with a substantial morbidity and mortality due to progression to cirrhosis and hepatocellular carcinoma. All causes of chronic liver disease may lead to fibrosis.
- Conditions
- Hepatitis C, Hepatitis B, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
- Trial name
- ELF (NCT02044523)
- Testing
- Transient elastography, acoustic radiation force impulse, magnetic resonance elastography
- Where
- Canada
- Volunteers
- 108 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Non-Alcoholic Fatty Liver Disease
Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries.
- Trial name
- NCT06863376
- Testing
- Carbocysteine 375 MG, Physical activity, walking, and calorie restriction
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Tanta University
Non-Alcoholic Fatty Liver Disease, Chronic Kidney Diseases
Assessment of Renal Changes in Patients With Non Alcoholic Fatty Liver Disease
Assess the renal changes in patients with non-alcoholic fatty liver (NAFLD).
- Trial name
- NCT03487068
- Testing
- The FibroScan device
- Volunteers
- 50 people
- Sponsor
- Assiut University
MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Chrononutrition/ Chronotoxicity Intervention in People With Metabolic-associated Steatotic Liver Disease.
The goal of this clinical trial is to study the effect of a time-restricted eating (TRE) dietary pattern combined with a time of consumption restriction about the daily portions of fruits and vegetables in people diagnosed with…
- Conditions
- MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD, NAFLD - Non-Alcoholic Fatty Liver Disease
- Trial name
- CHRONOMASLD (NCT06705868)
- Testing
- Diet-Time-restricted eating (TRE), Lifestyle Management
- Where
- Cyprus
- Volunteers
- 150 people
- Sponsor
- Cyprus University of Technology
NAFLD (Nonalcoholic Fatty Liver Disease)
Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions
It is a 12-week study. The participants will follow three different diets, and during each diet period, and the participants will wear our device, and blood samples will be collected.
- Trial name
- NCT06932289
- Testing
- Mediterranean diet (MED), high-fat/low carb diet (HF/LC), and low-fat diet (LF), The integrated sweat sensor and vascular sensor (wearable), continuous glucose monitor (CGM)
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- VA Greater Los Angeles Healthcare System
Liver Disease Chronic, Fibrosis, Liver
Effectiveness of Ultrasound in Liver Stiffness and Fat Quantification
Liver stiffness is a marker for scarring of the liver, which occurs after damage from various liver conditions. Scarring prevents normal liver function and can lead to liver failure.
- Conditions
- Liver Disease Chronic, Fibrosis, Liver, Liver Steatoses, Liver Fat
- Trial name
- NCT06111859
- Testing
- Ultrasound based Elastography and fat quantification
- Where
- United Kingdom
- Volunteers
- 180 people
- Sponsor
- King's College Hospital NHS Trust
Non-alcoholic Fatty Liver Disease
Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia
The purpose of this study is to examine whether non-alcoholic fatty liver disease (NAFLD) is associated with hepatic glucagon resistance and hyperglucagonemia.
- Trial name
- NCT02337660
- Testing
- Liver biopsy, Pancreatic clamp
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Nonalcoholic Steatohepatitis (NASH)
A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
This optional sub study is a part of the phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)
- Trial name
- NCT05320146
- Testing
- MRI-PDFF
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Corcept Therapeutics
MASLD, T2DM (Type 2 Diabetes Mellitus)
Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers
The goal of this observational study is to prospectively develop and validate a non-invasive scoring system based on metabolic markers, proteomic, and transcriptomic profiles to accurately screen, diagnose, stage, and monitor…
- Conditions
- MASLD, T2DM (Type 2 Diabetes Mellitus), Non-alcoholic Fatty Liver Disease (NAFLD), Obesity
- Trial name
- ENSURE-MASLD (NCT07172997)
- Testing
- Bariatric Surgery
- Where
- 2 sites in Bahrain
- Volunteers
- 163 people
- Sponsor
- Royal College of Surgeons in Ireland - Medical University of Bahrain
Non Alcoholic Fatty Liver Disease
Prevention and Reversion of NAFLD in Obese Patients With Metabolic Syndrome by Mediterranean Diet and Physical Activity
This prospective randomized trial evaluates the role of customized dietary and physical activity intervention on the progression of Non-Alcoholic Fatty Liver Disease (NAFLD) in patients with obesity and presenting at least three…
- Trial name
- FLIPAN (NCT04442620)
- Testing
- Physical activity and Mediterranean Diet (PA-MD), High meal frequency of Mediterranean Diet (HMF-MD), Control diet (CD)
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- University of the Balearic Islands
NASH - Nonalcoholic Steatohepatitis
Novel MRE Technique to Assess a Risk Factor for Liver Cancer
The aim of this proposal is to investigate a novel imaging method to identify patients with non-alcoholic steatohepatitis (NASH) who are at risk for hepatocellular carcinoma (HCC).
- Trial name
- NCT05165446
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Natalie Torok
Healthy, NAFLD
DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.
The primary objective of this study is to evaluate the effect of itraconazole, a strong inhibitor)of cytochrome P4503A , and phenytoin a strong inducer of cytochrome P450 3A, CYP3A4, CYP1A2 and CYP2C19 on the pharmacokinetics of…
- Trial name
- NCT04845646
- Testing
- ASC41, Itraconazole, Phenytoin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.)
Endoscopic Ultrasound involves the placement of a small flexible camera through the mouth and into the stomach to image various parts of the body.
- Trial name
- NAFLD (NCT00586313)
- Testing
- Tru-cut biopsy, Tru-cut
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Indiana University
Nonalcoholic Steatohepatitis (NASH)
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of CS0159 in subjects with Non-Alcoholic Steatohepatitis (NASH)
- Trial name
- NCT05591079
- Testing
- CS0159 (Linafexor)
- Where
- 17 sites in United States
- Volunteers
- 99 people
- Sponsor
- Cascade Pharmaceuticals, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.